FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

JOHNSON DAVID LEE		 2. Issuer Name and Ticker or Trading Symbol

Global Blood Therapeutics, Inc. [ GBT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Commercial Officer
(Last)          (First)          (Middle)

C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD.		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/5/2022
(Street)

SOUTH SAN FRANCISCO, CA 94080
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9/28/2022  G  V 22000 D$0.00 34384 D  
Common Stock 10/5/2022  D  34384 D (1)(2)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units  (3)10/5/2022  D     3125   (4) (4)Common Stock 3125  (4)0 D  
Restricted Stock Units  (3)10/5/2022  D     10935   (4) (4)Common Stock 10935  (4)0 D  
Restricted Stock Units  (3)10/5/2022  D     13814   (4) (4)Common Stock 13814  (4)0 D  
Restricted Stock Units  (3)10/5/2022  D     15460   (4) (4)Common Stock 15460  (4)0 D  
Restricted Stock Units  (3)10/5/2022  D     26454   (5) (5)Common Stock 26454  (5)0 D  
Restricted Stock Units  (3)10/5/2022  D     42400   (6) (6)Common Stock 42400  (6)0 D  
Stock Option (Right to Buy) $54.05 10/5/2022  D     55000   (7) (7)Common Stock 55000  (7)0 D  
Stock Option (Right to Buy) $48.44 10/5/2022  D     40000   (7) (7)Common Stock 40000  (7)0 D  
Stock Option (Right to Buy) $65.82 10/5/2022  D     38500   (7) (7)Common Stock 38500  (7)0 D  
Stock Option (Right to Buy) $44.48 10/5/2022  D     38739   (7) (7)Common Stock 38739  (7)0 D  
Stock Option (Right to Buy) $29.87 10/5/2022  D     28628   (7) (7)Common Stock 28628  (7)0 D  
Explanation of Responses:
(1) This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
(2) (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
(3) Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.
(4) Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
(5) Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.
(6) Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.
(7) Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
JOHNSON DAVID LEE
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080

Chief Commercial Officer
Signatures
/s/ Miguel Carrillo, Attorney-in-Fact10/6/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Global Blood Therapeutics Charts.
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Global Blood Therapeutics Charts.